LexaGene owns the 2 original patents. Jack is the author.
Biotechs of this nature typically sell between $300M and $800M. Would like to see the upper end.
You are correct about the one time use cartridges being like the razor blade and high margin. They will make a ton on the sale of those. They have a lease to buy program for the LX2 that will make it easy for anyone to afford to own one. That will be a big assist for sales too.